| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 726.41M | $ 700.97M | $ 674.98M | $ 666.82M | $ 541.53M |
| Gross Profit | $ 576.66M | $ 530.54M | $ 490.31M | $ 467.53M | $ 401.28M |
| Operating Income | $ 33.30M | $ -73.37M | $ 87.67M | $ 60.02M | $ 89.92M |
| EBITDA | $ 122.50M | $ 29.12M | $ 154.59M | $ 140.38M | $ 113.95M |
| Net Income | $ 7.03M | $ -99.56M | $ 41.95M | $ 15.91M | $ 41.98M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 238.42M | $ 484.62M | $ 278.58M | $ 288.65M | $ 656.41M |
| Total Assets | $ 1.26B | $ 1.55B | $ 1.57B | $ 1.68B | $ 2.08B |
| Total Debt | $ 454.38M | $ 638.85M | $ 586.04M | $ 763.39M | $ 1.13B |
| Net Debt | $ 295.83M | $ 362.08M | $ 432.75M | $ 659.25M | $ 543.27M |
| Total Liabilities | $ 571.81M | $ 775.17M | $ 704.26M | $ 906.19M | $ 1.34B |
| Stockholders' Equity | $ 693.11M | $ 778.35M | $ 870.13M | $ 775.01M | $ 730.41M |
| Cash Flow | |||||
| Free Cash Flow | $ 136.66M | $ 178.75M | $ 139.49M | $ 115.20M | $ 79.85M |
| Operating Cash Flow | $ 151.99M | $ 189.39M | $ 154.65M | $ 145.27M | $ 125.72M |
| Investing Cash Flow | $ 99.48M | $ -83.28M | $ 77.54M | $ -225.19M | $ -20.79M |
| Financing Cash Flow | $ -369.63M | $ 17.36M | $ -183.03M | $ -401.53M | $ 380.69M |
Pacira Pharmaceuticals (CH:82P)
:82P
